Topic of Study: Inflammatory Bowel Disease The goals of this prospective cohort study are to study the natural history of IBD, prevalence and incidence of comorbidities, and targeted adverse events, as well as utilization patterns and comparative effectiveness and safety of approved IBD treatments. (Clinicaltrials.gov ID#: NCT03162549).

Topic of Study: Breast Cancer This is a Phase III, Double-blind, Randomized study to assess switching to AZD9833 (a Next Generation, Oral SERD) plus a CDK4/6 Inhibitor (Palbociclib or Abemaciclib) versus continuing an Aromatase Inhibitor (Letrozole or Anastrozole) plus CDK4/6 Inhibitor in patients with Hormone receptor positive (HR+), HER2 negative metastatic breast cancer with a detectable ESR1 Mutation without disease progression during first line treatment. - A ctDNA Guided Early Switch Study (Clinicaltrials.gov ID#: NCT04964934) 

Topic of Study: Breast Cancer This study is a randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for first line, metastatic HER+2 breast cancer (Clinicaltrials.gov ID#: NCT05132582).